Compare ALLR & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLR | HSCS |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 15.8M |
| IPO Year | 2021 | 2022 |
| Metric | ALLR | HSCS |
|---|---|---|
| Price | $0.98 | $3.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 107.6K | ★ 144.8K |
| Earning Date | 11-13-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,000.00 | $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $1.63 |
| 52 Week High | $1.84 | $5.25 |
| Indicator | ALLR | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 40.47 |
| Support Level | $0.90 | $1.84 |
| Resistance Level | $1.00 | $3.44 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 18.69 | 3.59 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.